A Phase 1 interventional study of MEDI4920 3 mg and MEDI4920 10 mg in Healthy Volunteer, sponsored by MedImmune LLC. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
First submitted after MedImmune LLC became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
Other: Placebo
Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
Biological: MEDI4920 3 mg
Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
Biological: MEDI4920 10 mg
Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
Biological: MEDI4920 30 mg
Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
Biological: MEDI4920 100 mg
Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
Biological: MEDI4920 300 mg
Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
Biological: MEDI4920 1000 mg
Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
Biological: MEDI4920 3000 mg
Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug. A TEAE is defined as the event with onset after the start of infusion (Day 1) to Day 113 or early discontinuation visit inclusive. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0.
Time frame: The start of study drug administration (Day 1) to the follow-up period (Day 113) or early discontinuation visit
Maximum Observed Plasma Concentration (Cmax) of MEDI4920
The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI4920
The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI4920
The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Dose-normalized AUC0-inf (AUC0-infinity/D) of MEDI4920
The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI4920 dose. The AUC (0-infinity)/D was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Terminal Elimination Half Life (t1/2) of MEDI4920
The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Systemic Clearance (CL) of MEDI4920
The systemic clearance (CL) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Volume of Distribution at Steady-state (Vss) of MEDI4920
The volume of distribution at steady-state (Vss) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Volume of Distribution Based on Terminal Phase (Vz) of MEDI4920
The volume of distribution based on terminal phase (Vz) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Percentage of Participants Positive for Anti-drug Antibodies (ADA)
Plasma samples were collected for assessment of anti-drug antibodies (ADA) against MEDI4920. The incidence of positive serum antibodies to MEDI4920 are presented.
Time frame: Baseline (pre-infusion on Day 1) and post-baseline Days 15, 29, 57, and 113 or early discontinuation visit, whichever occurred first
T-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) Concentration
The T-cell dependent antibody response (TDAR) assay measures the immune response (ie, antibody production) to an introduced antigen, keyhole limpet hemocyanin (KLH). The KLH is a potent immunostimulating protein with an extensive history of safe and effective use in vaccine development and immunological research. TDAR was evaluated by measuring anti-KLH IgG titers at a time point consistent with the expected timing for antibody responses following immunization. The primary time point for the analysis of the TDAR to KLH was Day 43. The data was presented for geometric mean ratio (MEDI4920/placebo) estimated from the dose response model.
Time frame: Day 43
Healthy adult male and female participants were recruited in a blinded manner. The study was conducted at one site in the United Kingdom.
| Milestone | Placebo | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 12 | 2 | 2 | 8 | 8 | 8 | 8 | 8 |
| Completed | 12 | 2 | 2 | 8 | 8 | 8 | 8 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug. A TEAE is defined as the event with onset after the start of infusion (Day 1) to Day 113 or early discontinuation visit inclusive. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0.
| Participants | Placebo | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|---|
| TEAEs | 10 | 1 | 1 | 5 | 8 | 3 | 5 | 7 |
| TESAEs | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
| microgram per milliliter (µg/mL) | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of MEDI4920 | 1.00 ± NA | 4.46 ± NA | 7.97 ± 0.873 | 23.6 ± 2.76 | 85.6 ± 17.6 | 289 ± 58.1 | 960 ± 126 |
The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
| microgram*day per milliliter (µg*d/mL) | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI4920 | 3.64 ± NA | 19.3 ± NA | 53.4 ± 10.9 | 151 ± 20.2 | 581 ± 38.3 | 2090 ± 394 | 6640 ± 553 |
The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
| microgram*day per milliliter (µg*d/mL) | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI4920 | 4.60 ± NA | 20.5 ± NA | 54.8 ± 11.0 | 152 ± 20.2 | 583 ± 37.8 | 2090 ± 394 | 6640 ± 547 |
The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI4920 dose. The AUC (0-infinity)/D was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
| µg*d/mL/mg | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|
| Dose-normalized AUC0-inf (AUC0-infinity/D) of MEDI4920 | 1.53 ± NA | 2.05 ± NA | 1.83 ± 0.366 | 1.52 ± 0.202 | 1.94 ± 0.126 | 2.09 ± 0.394 | 2.21 ± 0.182 |
The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
| Day(s) | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|
| Terminal Elimination Half Life (t1/2) of MEDI4920 | 4.41 ± NA | 5.35 ± NA | 5.31 ± 2.30 | 5.49 ± 1.59 | 8.86 ± 1.60 | 9.68 ± 1.25 | 10.1 ± 1.87 |
The systemic clearance (CL) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
| milliliter per day (mL/day) | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|
| Systemic Clearance (CL) of MEDI4920 | 661 ± NA | 487 ± NA | 564 ± 96.8 | 668 ± 90.4 | 517 ± 33.5 | 494 ± 102 | 454 ± 37.9 |
The volume of distribution at steady-state (Vss) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
| milliliter (mL) | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|
| Volume of Distribution at Steady-state (Vss) of MEDI4920 | 3980 ± NA | 3290 ± NA | 4280 ± 684 | 5560 ± 806 | 5180 ± 811 | 5450 ± 1150 | 4900 ± 715 |
The volume of distribution based on terminal phase (Vz) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.
| milliliter (mL) | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|
| Volume of Distribution Based on Terminal Phase (Vz) of MEDI4920 | 4130 ± NA | 3760 ± NA | 4080 ± 1090 | 5230 ± 1360 | 6590 ± 1160 | 6880 ± 1520 | 6600 ± 1190 |
Plasma samples were collected for assessment of anti-drug antibodies (ADA) against MEDI4920. The incidence of positive serum antibodies to MEDI4920 are presented.
| Percentage of participants | Placebo | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|---|
| Baseline ADA positive | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Post-baseline ADA positive | 8.3 | 50 | 100 | 100 | 87.5 | 37.5 | 37.5 | 12.5 |
The T-cell dependent antibody response (TDAR) assay measures the immune response (ie, antibody production) to an introduced antigen, keyhole limpet hemocyanin (KLH). The KLH is a potent immunostimulating protein with an extensive history of safe and effective use in vaccine development and immunological research. TDAR was evaluated by measuring anti-KLH IgG titers at a time point consistent with the expected timing for antibody responses following immunization. The primary time point for the analysis of the TDAR to KLH was Day 43. The data was presented for geometric mean ratio (MEDI4920/placebo) estimated from the dose response model.
| nanogram per milliliter (ng/mL) | Placebo | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|---|
| T-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) Concentration | NA (NA to NA) | 0.99 (0.96 to 1.01) | 0.96 (0.89 to 1.03) | 0.88 (0.72 to 1.08) | 0.68 (0.41 to 1.14) | 0.42 (0.18 to 0.97) | 0.22 (0.10 to 0.47) | 0.14 (0.06 to 0.32) |
Collected over Adverse events were collected from time of signature of informed consent, throughout the treatment period, and the follow-up period (through Day 113 or early discontinuation visit).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/12 (0%) | 1/12 (8.3%) | 10/12 (83.3%) |
| MEDI4920 3 mg | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| MEDI4920 10 mg | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| MEDI4920 30 mg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| MEDI4920 100 mg | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| MEDI4920 300 mg | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| MEDI4920 1000 mg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| MEDI4920 3000 mg | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Event | Placebo | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|---|
| Tibia fractureInjury, poisoning and procedural complications | 1/12 | 0/2 | 0/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| Event | Placebo | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/12 | 0/2 | 1/2 | 0/8 | 5/8 | 1/8 | 1/8 | 2/8 |
| BlepharitisEye disorders | 0/12 | 1/2 | 0/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/2 | 1/2 | 0/8 | 0/8 | 1/8 | 2/8 | 1/8 |
| VomitingGastrointestinal disorders | 1/12 | 0/2 | 1/2 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 |
| HordeolumInfections and infestations | 0/12 | 1/2 | 0/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 4/12 | 0/2 | 1/2 | 2/8 | 0/8 | 1/8 | 1/8 | 3/8 |
| Memory impairmentNervous system disorders | 0/12 | 1/2 | 0/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/12 | 0/2 | 1/2 | 0/8 | 1/8 | 0/8 | 0/8 | 1/8 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/12 | 0/2 | 1/2 | 1/8 | 1/8 | 0/8 | 0/8 | 1/8 |
| Ear discomfortEar and labyrinth disorders | 0/12 | 0/2 | 0/2 | 0/8 | 2/8 | 0/8 | 0/8 | 0/8 |
As-treated population included all participants who received any study drug. Two participants were erroneously randomized to MEDI4920 10 mg group due to the IXRS system not being opened for start of MEDI4920 30 mg group. However, these participants received the 30 mg dose.
| Age, Continuous(Years) | Placebo | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg | TOTAL |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 33.3 ± 8.9 | 27.5 ± 4.9 | 26.0 ± 1.4 | 27.8 ± 12.3 | 28.1 ± 10.1 | 38.4 ± 9.3 | 33.3 ± 9.2 | 32.0 ± 9.8 | 31.8 ± 9.8 |
| Sex: Female, Male(Participants) | Placebo | MEDI4920 3 mg | MEDI4920 10 mg | MEDI4920 30 mg | MEDI4920 100 mg | MEDI4920 300 mg | MEDI4920 1000 mg | MEDI4920 3000 mg | TOTAL |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 12 | 2 | 2 | 8 | 8 | 8 | 8 | 8 | 56 |
Ran from May 2014 to primary completion in May 2016, 23 months.
Results were first posted in Feb 2019, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dazodalibep